|
Hemato-oncology / Original Article
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
Young Hoon Park, Dae-Young Kim, Yeung-Chul Mun, Eun Kyung Cho, Jae Hoon Lee, Deog-Yeon Jo, Inho Kim, Sung-Soo Yoon, Seon Yang Park, Byoungkook Kim, Soo-Mee Bang, Hawk Kim, Young Joo Min, Jae Hoo Park, Jong Jin Seo, Hyung Nam Moon, Moon Hee Lee, Chul Soo Kim, Won Sik Lee, So Young Chong, Doyeun Oh, Dae Young Zang, Kyung Hee Lee, Myung Soo Hyun, Heung Sik Kim, Sung-Hyun Kim, Hyukchan Kwon, Hyo Jin Kim, Kyung Tae Park, Sung Hwa Bae, Hun Mo Ryoo, Jung Hye Choi, Myung-Ju Ahn, Hwi-Joong Yoon, Sung-Hyun Nam, Bong-Seog Kim, Chu-Myong Seong
Korean J Intern Med. 2022;37(4):841-850. Published online June 28, 2022
Background/Aims: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL).
Methods: We included 87 patients with newly diagnosed acute myeloid l..
|
|
|
Hemato-oncology / Original Article
How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey
Ja Min Byun, Soo-Mee Bang, Eun-Ji Choi, Ki-Seong Eom, Chul Won Jung, Hye-seon Kim, Jiwon Park, Chul Won Choi
Korean J Intern Med. 2022;37(2):444-454. Published online February 28, 2022
Background/Aims: Recent advances in the understanding of the pathophysiology of myeloproliferative neoplasms (MPN) were not paralleled with advances in treatment options; thus many questions regarding optimal MPN management remain unanswered. Here, we report the results of descriptive survey study o..
|
|
|
Review
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
Sung-Yong Kim, Sung Hwa Bae, Soo-Mee Bang, Ki-Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo-Jeong Kim, Yeung-Chul Mun, Seung-Hyun Nam, Jinny Park, Jong-Ho Won, Chul Won Choi
Korean J Intern Med. 2021;36(1):45-62. Published online December 4, 2020
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional som..
|
|
|
Hemato-oncology / Original Article
Prominent seasonal variation in pulmonary embolism than deep vein thrombosis incidence: a Korean venous thrombosis epidemiology study
Junshik Hong, Ju Hyun Lee, Ji Yun Lee, Jeong-Ok Lee, Won-Il Choi, Soyeon Ahn, Youn-Hee Lim, Soo-Mee Bang, Doyeun Oh
Korean J Intern Med. 2020;35(3):682-691. Published online October 25, 2019
Background/Aims: Seasonal variation is an environmental factor proposed to affect the incidence of venous thromboembolism (VTE). However, VTE seasonal variation is not well studied in Asian populations, which have different genetic determinants of VTE compared to Westerners. The present study aimed ..
|
|
|
Hemato-oncology / Original Article
Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
Ho-Young Yhim, Won-Il Choi, Sung-Hyun Kim, Seung-Hyun Nam, Kyoung Ha Kim, Yeung-Chul Mun, Doyeun Oh, Hun-Gyu Hwang, Keun-Wook Lee, Eun-Kee Song, Yong Shik Kwon, Soo-Mee Bang
Korean J Intern Med. 2019;34(5):1125-1135. Published online May 23, 2018
Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients.
Methods: In th..
|
|
|
Hemato-oncology / Review
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won
Korean J Intern Med. 2015;30(6):771-788. Published online October 30, 2015
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysio..
|
|
|
Original Article
A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
Hye Jung Chang, Jae Hoon Lee, Young Rok Do, Sung-Hwa Bae, Jung-Lim Lee, Seung Hyun Nam, Sung-Soo Yoon, Soo-Mee Bang
Korean J Intern Med. 2011;26(4):403-409. Published online November 28, 2011
Background/AimsThe clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment. Because the side effects of thalidomid..
|
|
|
Original Article
Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
Kyu-Hyoung Lim, Ho-Il Yoon, Young Ae Kang, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jae Ho Lee, Choon-Taek Lee, Jong Seok Lee
Korean J Intern Med. 2010;25(1):86-92. Published online February 26, 2010
Background/AimsThe aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymph..
|
|
|
Original Article
Cost Analysis of Iron-Related Complications in a Single Institute
Ki Hwan Kim, Jin Won Kim, Ji young Rhee, Min-Kyung Kim, Byung-Su Kim, Inho Kim, Soo-Mee Bang, Sung-Soo Yoon, Jong-Seok Lee, Kyou-Sup Han, Seonyang Park, Byoung Kook Kim
Korean J Intern Med. 2009;24(1):33-36. Published online March 6, 2009
Background/AimsThe financial burden of caring for iron-related complications (IRCs) is an emerging medical problem in Korea, as in Western countries. We produced a preliminary estimate of the costs of treating patients for IRCs. Methods<.. </div>
</td>
</tr>
</table>
</td>
</tr> <tr>
<td colspan="3">
<table cellpadding="0" cellspacing="0" border="0" id="article_tbl_18152" style="border:1px solid #ffffff; border-bottom:1px solid #E2E2E2;">
<tr>
<td style="padding-left:10px;padding-right:27px; padding-top:10px;padding-bottom:10px;width:733px;" valign="top" >
<div style="color:#C62F37;font-family:'Noto Sans KR', 'Nanum Gothic', sans-serif;">Original Article </div>
<a class="artiletitle" href="/journal/view.php?number=18152" onmouseover="showAbstract('18152' );" onmouseout="hideAbstract('18152' );"><b><font><italic>Epstein-Barr Virus</italic>-Positivity in Tumor has no Correlation with the Clinical Outcomes of Patients with Angioimmunoblastic T-cell Lymphoma</font></b></a>
<div style="padding-top:2px;padding-left:0px" class="article_authors">Yuna Lee, Keun-Wook Lee, Jee-Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Byeong-Bae Park, Won Seok Kim, Cheolwon Suh, Jung Hun Kang, Baek Yeol Ryoo, Jae Hoon Lee, Dong Bok Shin</div>
<div style="padding-top:2px;padding-left:0px" class="article_issue">
<em>Korean J Intern Med.</em> 2008;23(1):30-36. Published online March 20, 2008 </div>
<div class="doi">DOI: <a href="https://doi.org/10.3904/kjim.2008.23.1.30"><font class="doi">https://doi.org/10.3904/kjim.2008.23.1.30</font></a>
<a href="/journal/CitedByRenew.php?number=18152" onclick="window.open(this.href, 'CrossRef Citedby', 'width=800,height=800,scrollbars=yes');return false;" style="color:#DD434F;font-size:10pt;"> Crossref 13</a>
</div>
<div class="etc" style="padding-top:5px;text-align: right;">
<a href='/journal/view.php?number=18152' style='text-decoration:underline;color:#2046f8'><img src='/image/button/fulltext.gif' alt='Full Text' /></a> <a href='/journal/view.php?viewtype=pubreader&number=18152' style='text-decoration:underline;color:#2046f8'><img src='/image/button/pubreader.gif' alt='PubReader' /></a> <a style='cursor: pointer;' onclick='journal_download("epub", "18152", "path=L2hvbWUvdmlydHVhbC9rYWltL2pvdXJuYWwvdXBsb2FkL2VwdWIva2ppbS0yMy0zMC5lcHVi&filename=a2ppbS0yMy0zMC5lcHVi")'><img src='/image/button/epub.gif' alt='ePub' /></a> <a style='cursor: pointer;' onclick='journal_download("pdf", "18152", "kjim-23-30.pdf")'><img src='/image/button/pdf.gif' alt='PDF' /></a> </div>
<div id="18152" style="display:none;padding-top:10px;padding-left:0px; color:#7b7b7b">
<sec><title>Background/AimsEpstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear. This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone ..
|
|
|
Case Report
Castleman Disease Presenting with Jaundice: A Case with the Multicentric Hyaline Vascular Variant
Jun bean Park, Jin Hyeok Hwang, Haeryoung Kim, Hyung Sim Choe, Yu Kyeong Kim, Hong Bin Kim, Soo-Mee Bang
Korean J Intern Med. 2007;22(2):113-117. Published online June 30, 2007
Castleman disease (CD) is a rare lymphoproliferative disorder of unknown etiology with different clinical manifestations. A previous healthy 50 year-old man was hospitalized for right upper quadrant (RUQ) abdominal pain. He had jaundice and a 1 cm-sized lymph node in the right supraclavicular are..
|
|
|
Original Article
Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study
Sang Hoon Han, Se Hoon Park, Jung Ho Kim, Jong Jun Lee, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Keon Kug Kim, Yeon Ho Park, Jeong Nam Lee, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2006;21(4):225-229. Published online December 31, 2006
BackgroundThalidomide has been reported to have antitumor activity for treating metastatic hepatocellular carcinoma (HCC). We evaluated the safety and efficacy of using thalidomide for treating selected patients with unresectable or metastatic HCC, and their disease was refrac..
|
|
|
Original Article
Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
Soo-Mee Bang, Jeong Yeal Ahn, Jiyoon Park, Soo Jin Yoo, Se Hoon Park, Eun Mi Nam, Pil Whan Park, Yiel Hea Seo, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2006;21(4):219-224. Published online December 31, 2006
BackgroundWe investigated the Janus kinase 2 (JAK2) mutation and its diagnostic value in patients suffering with non BCR/ABL myeloproliferative diseases (nMPD) or other reactive conditions. Methods..
|
|
|
Case Report
Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
Yuna Lee, Sun Young Kyung, Soo Jin Choi, Soo-Mee Bang, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2006;21(3):183-186. Published online September 30, 2006
Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's lymphoma either in combination with other drugs or as a single agent. The CD20 antigen is expressed on 95% of B-cell lymphoma cells and normal B-cells but, is..
|
|
|
Original Article
High-dose Versus Low-dose Cyclophosphamide in Combination with G-CSF for Peripheral Blood Progenitor Cell Mobilization
Jin Seok Ahn, Seonyang Park, Seock-Ah Im, Sung-Soo Yoon, Jong-Seok Lee, Byoung Kook Kim, Soo-Mee Bang, Eun Kyung Cho, Jae Hoon Lee, Chul Won Jung, Hugh Chul Kim, Chu Myung Seong, Moon Hee Lee, Chul Soo Kim, Keun Seok Lee, Jung Ae Lee, Myung-Ju Ahn
Korean J Intern Med. 2005;20(3):224-231. Published online September 30, 2005
BackgroundTo compare the mobilizing effects and toxicities of two different doses of cyclophosphamide (CY) plus lenograstim (glycosylated G-CSF), we performed a prospective randomized study by enrolling patients suffering with either high-risk Non-Hodgkin's lymphoma (NHL) or b..
|
|
|
